DBV Technologies
Save
–
Market cap
–
Current P/E
–
Forward P/E
About
DBV Technologies S. A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies.
Similar securities
Based on sector and market capitalization
Report issue